Senti Biosciences (NASDAQ:SNTI - Get Free Report) was upgraded by equities researchers at Wall Street Zen to a "sell" rating in a report released on Saturday.
Several other research firms also recently issued reports on SNTI. Laidlaw began coverage on Senti Biosciences in a report on Friday, June 6th. They set a "buy" rating and a $5.00 price objective on the stock. Chardan Capital reiterated a "buy" rating and set a $12.00 price target on shares of Senti Biosciences in a report on Thursday, June 12th.
View Our Latest Report on Senti Biosciences
Senti Biosciences Price Performance
Shares of SNTI opened at $2.13 on Friday. The business's fifty day moving average price is $2.81 and its 200 day moving average price is $3.46. Senti Biosciences has a 12-month low of $1.52 and a 12-month high of $16.94. The stock has a market capitalization of $55.55 million, a PE ratio of -0.20 and a beta of 2.09.
Senti Biosciences (NASDAQ:SNTI - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.85). The firm had revenue of $1.30 million during the quarter, compared to the consensus estimate of $1.30 million. As a group, research analysts anticipate that Senti Biosciences will post -14.54 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Senti Biosciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC bought a new position in Senti Biosciences in the 4th quarter worth approximately $181,000. Virtu Financial LLC acquired a new stake in Senti Biosciences in the 4th quarter valued at $47,000. Nantahala Capital Management LLC acquired a new position in Senti Biosciences in the first quarter worth $2,984,000. Finally, Heights Capital Management Inc. acquired a new position in Senti Biosciences in the first quarter worth $2,520,000. 25.73% of the stock is currently owned by institutional investors and hedge funds.
About Senti Biosciences
(
Get Free Report)
Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Senti Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Senti Biosciences wasn't on the list.
While Senti Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
